Arena Pharmaceuticals - ARNA Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Arena Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares.
View analyst ratings for Arena Pharmaceuticals or view top-rated stocks.

10 brokerages have issued twelve-month price targets for Arena Pharmaceuticals' shares. Their ARNA stock forecasts range from $71.00 to $105.00. On average, they predict Arena Pharmaceuticals' share price to reach $95.60 in the next year. This suggests that the stock has a possible downside of 4.4%.
View analysts' price targets for Arena Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.53) by $0.68. During the same quarter in the prior year, the firm earned ($1.69) EPS.

Arena Pharmaceuticals shares reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

16 employees have rated Arena Pharmaceuticals CEO Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among Arena Pharmaceuticals' employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

One share of ARNA stock can currently be purchased for approximately $99.99.

Arena Pharmaceuticals (NASDAQ:ARNA) has a market capitalization of $6.17 billion and generates $50,000.00 in revenue each year. The biopharmaceutical company earns $-616,430,000.00 in net income (profit) each year or ($10.13) on an earnings per share basis.

Arena Pharmaceuticals employs 448 workers across the globe.

Arena Pharmaceuticals was founded in 1977.

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The official website for Arena Pharmaceuticals is www.arenapharm.com. The biopharmaceutical company can be reached via phone at (858) 453-7200, via email at ir@arenapharm.com, or via fax at 858-453-7210.